A research label is not a care pathway

Look at what the page is offering

FDA means Food and Drug Administration. This agency reviews drugs in the US.

Letters in its September 2026 record challenged websites that labelled products for research while promoting their use in people.

The agency looked at what a website said the product was for. Calling it “research” did not erase those claims.

Those letters state FDA’s position about specific firms; they are not decisions from a court.

A page promising a change in fat or muscle still needs to answer a plain question: what exactly is being offered, and through what kind of care?

Put the offer beside the treatment route

In a weight-care offer, retatrutide and cagrilintide name drug ingredients, not approved brands. In September 2026, FDA said neither had been shown to work and be safe for any condition. FDA said federal law did not allow either ingredient in a compounded medicine.

A promise of a prescription does not remove that compounding ban. Ask the person offering treatment whether the product is approved and whether a pharmacy is allowed to make it.